Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.

Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB.

J Pharmacol Exp Ther. 2019 Jun;369(3):364-374. doi: 10.1124/jpet.118.255695. Epub 2019 Mar 27.

PMID:
30918068
2.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
3.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
4.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2019 Mar 15;147:11-27. doi: 10.1016/j.neuropharm.2018.05.035. Epub 2018 Jun 1. Review.

PMID:
29907424
5.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
7.

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.

8.

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM.

Neuropharmacology. 2015 Oct;97:306-11. doi: 10.1016/j.neuropharm.2015.05.033. Epub 2015 Jun 10.

PMID:
26071982
9.

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

Huot P, Johnston TH, Fox SH, Brotchie JM.

Synapse. 2015 Mar;69(3):99-102. doi: 10.1002/syn.21801.

PMID:
25559284
10.

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM.

Behav Pharmacol. 2015 Feb;26(1-2):101-8. doi: 10.1097/FBP.0000000000000096.

PMID:
25303957
11.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18.

PMID:
24447715
12.

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.

13.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM.

Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14.

PMID:
23770260
14.

Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice.

Kirshenbaum GS, Dawson N, Mullins JG, Johnston TH, Drinkhill MJ, Edwards IJ, Fox SH, Pratt JA, Brotchie JM, Roder JC, Clapcote SJ.

PLoS One. 2013;8(3):e60141. doi: 10.1371/journal.pone.0060141. Epub 2013 Mar 20.

15.

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Review.

PMID:
23319549
16.

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM.

Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3.

PMID:
23281915
17.

The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

PLoS One. 2012;7(9):e45587. doi: 10.1371/journal.pone.0045587. Epub 2012 Sep 20.

18.

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.

Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E.

Mov Disord. 2012 Sep 15;27(11):1373-8. doi: 10.1002/mds.25133. Epub 2012 Sep 13. Review.

PMID:
22976821
19.

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM.

Parkinsonism Relat Disord. 2013 Feb;19(2):260-4. doi: 10.1016/j.parkreldis.2012.07.001. Epub 2012 Aug 14.

PMID:
22901956
20.

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Neuropharmacology. 2012 Oct;63(5):829-36. doi: 10.1016/j.neuropharm.2012.06.012. Epub 2012 Jun 18.

PMID:
22722022
21.

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2012 Aug;342(2):576-85. doi: 10.1124/jpet.112.195693. Epub 2012 May 22.

PMID:
22619253
22.

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.

Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, Brotchie JM, Fox SH.

Mov Disord. 2012 May;27(6):735-42. doi: 10.1002/mds.24964. Epub 2012 Mar 14.

PMID:
22419526
23.

A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.

Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, Piggott MJ, Brotchie JM.

FASEB J. 2012 May;26(5):2154-63. doi: 10.1096/fj.11-195016. Epub 2012 Feb 17.

PMID:
22345403
24.

Experimental Models of l-DOPA-Induced Dyskinesia.

Johnston TH, Lane EL.

Int Rev Neurobiol. 2011;98:55-93. doi: 10.1016/B978-0-12-381328-2.00003-1.

PMID:
21907083
25.

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

J Neurosci. 2011 May 11;31(19):7190-8. doi: 10.1523/JNEUROSCI.1171-11.2011.

26.

The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM.

Mov Disord. 2011 Jun;26(7):1225-33. doi: 10.1002/mds.23631. Epub 2011 Apr 4.

PMID:
21465551
27.

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.

Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM.

PLoS One. 2011 Mar 7;6(3):e17698. doi: 10.1371/journal.pone.0017698.

28.

Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains.

Thiele SL, Warre R, Khademullah CS, Fahana N, Lo C, Lam D, Talwar S, Johnston TH, Brotchie JM, Nash JE.

J Neurosci Methods. 2011 Apr 30;197(2):193-208. doi: 10.1016/j.jneumeth.2011.02.012. Epub 2011 Feb 23.

PMID:
21352853
29.

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM.

Neurobiol Aging. 2012 Jan;33(1):207.e9-19. doi: 10.1016/j.neurobiolaging.2010.09.011. Epub 2010 Nov 3.

PMID:
21051107
31.

Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism.

Warre R, Thiele S, Talwar S, Kamal M, Johnston TH, Wang S, Lam D, Lo C, Khademullah CS, Perera G, Reyes G, Sun XS, Brotchie JM, Nash JE.

Neurobiol Dis. 2011 Mar;41(3):591-604. doi: 10.1016/j.nbd.2010.10.013. Epub 2010 Oct 21.

PMID:
20971190
32.

Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.

Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM.

J Pharmacol Exp Ther. 2011 Feb;336(2):423-30. doi: 10.1124/jpet.110.169532. Epub 2010 Oct 21.

PMID:
20966038
33.

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.

Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM.

Mov Disord. 2010 Oct 15;25(13):2084-93. doi: 10.1002/mds.23172.

PMID:
20824735
34.

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations.

Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH.

Mov Disord. 2010 Jul 30;25(10):1399-408. doi: 10.1002/mds.23083.

PMID:
20629135
35.

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM.

Neurobiol Aging. 2012 Jan;33(1):194.e5-15. doi: 10.1016/j.neurobiolaging.2010.04.035. Epub 2010 Jun 18.

PMID:
20561716
36.

Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

Johnston TH, van der Meij A, Brotchie JM, Fox SH.

Mov Disord. 2010 Jul 30;25(10):1379-90. doi: 10.1002/mds.23069.

PMID:
20310030
37.
38.

New insights into the organization of the basal ganglia.

Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM.

Curr Neurol Neurosci Rep. 2009 Jul;9(4):298-304.

PMID:
19515282
39.

Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques.

Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM.

J Pharmacol Exp Ther. 2009 Jan;328(1):276-83. doi: 10.1124/jpet.108.144097. Epub 2008 Oct 27.

PMID:
18955589
40.

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH.

Mov Disord. 2008 Oct 15;23(13):1922-5. doi: 10.1002/mds.22086.

PMID:
18759357
41.

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.

Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M.

Neuropharmacology. 2008 Sep;55(4):483-90. doi: 10.1016/j.neuropharm.2008.06.038. Epub 2008 Jun 27.

PMID:
18625257
42.

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD.

FASEB J. 2008 Jul;22(7):2488-97. doi: 10.1096/fj.07-095398. Epub 2008 Mar 25.

PMID:
18364399
43.
44.

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM.

Arch Neurol. 2006 Sep;63(9):1343-4. No abstract available.

PMID:
16966523
45.

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH.

Mov Disord. 2006 Nov;21(11):1879-91.

PMID:
16960862
46.

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Gomez-Ramirez J, Johnston TH, Visanji NP, Fox SH, Brotchie JM.

Mov Disord. 2006 Jun;21(6):839-46.

PMID:
16532454
47.

Drugs in development for Parkinson's disease: an update.

Johnston TH, Brotchie JM.

Curr Opin Investig Drugs. 2006 Jan;7(1):25-32. Review.

PMID:
16425668
48.

Advances in the delivery of treatments for Parkinson's disease.

Johnston TH, Fox SH, Brotchie JM.

Expert Opin Drug Deliv. 2005 Nov;2(6):1059-73. Review.

PMID:
16296809
49.

Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.

Nash JE, Johnston TH, Collingridge GL, Garner CC, Brotchie JM.

FASEB J. 2005 Apr;19(6):583-5. Epub 2005 Feb 9.

PMID:
15703272
50.

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.

Exp Neurol. 2005 Feb;191(2):243-50.

PMID:
15649479

Supplemental Content

Loading ...
Support Center